TY - JOUR T1 - Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections JF - medRxiv DO - 10.1101/2021.06.07.21258351 SP - 2021.06.07.21258351 AU - Liane Dupont AU - Luke B. Snell AU - Carl Graham AU - Jeffrey Seow AU - Blair Merrick AU - Thomas Lechmere AU - Sadie R. Hallett AU - Themoula Charalampous AU - Adela Alcolea-Medina AU - Isabella Huettner AU - Thomas J. A. Maguire AU - Sam Acors AU - Nathalia Almeida AU - Daniel Cox AU - Ruth E. Dickenson AU - Rui Pedro Galao AU - Jose M. Jimenez-Guardeño AU - Neophytos Kouphou AU - Marie Jose Lista AU - Suzanne Pickering AU - Ana Maria Ortega-Prieto AU - Harry Wilson AU - Helena Winstone AU - Cassandra Fairhead AU - Jia Su AU - Gaia Nebbia AU - Rahul Batra AU - Stuart Neil AU - Manu Shankar-Hari AU - Jonathan D. Edgeworth AU - Michael H. Malim AU - Katie J. Doores Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/08/2021.06.07.21258351.abstract N2 - As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross-neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by; King′s Together Rapid COVID–;19 Call awards to MHM, KJD and SJDN, MRC Discovery Award MC/PC/15068 to SJDN, KJD and MHM, Fondation Dormeur, Vaduz for funding equipment to KJD, Huo Family Foundation Award to MHM, KJD, MSH and SJDN, MRC Genotype–;to–;Phenotype UK National Virology Consortium (MR/W005611/1 to MHM, KJD and SJDN), MRC Programme Grant (MR/S023747/1 to MHM), Wellcome Trust Investigator Award 106223/Z/14/Z to MHM, NIAID Awards AI150472 and AI076119 to MHM. MSH is funded by the National Institute for Health Research Clinician Scientist Award (CS–;2016–;16–;011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. CG, SH and HW were supported by the MRC–;KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). SA was supported by an MRC–;KCL Doctoral Training Partnership in Biomedical Sciences industrial Collaborative Award in Science & Engineering (iCASE) in partnership with Orchard Therapeutics (MR/R015643/1). NA is funded by the Wellcome Trust PhD program Cell therapies and regenerative medicine (108874/Z/15/Z). This work was supported by the Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy′s and St. Thomas′ NHS Foundation Trust in partnership with King′s College London and King′s College Hospital NHS Foundation Trust. This study is part of the EDCTP2 programme supported by the European Union (grant number RIA2020EF–;3008 COVAB). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of surplus serum samples was approved by South Central REC 20/SC/0310.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data was used in this study and is not available for distribution outside the host organisations. ER -